As one of the main risk factors of cardiovascular and cerebrovascular diseases, hyperlipidemia has a great impact on the quality of life of patients. Statins, as first-line lipid-lowering drugs, have been clinically proven, but for high-risk patients with cardiovascular and cerebrovascular diseases caused by hyperlipidemia, the optimal lipid-lowering effect cannot be achieved by increasing the basic dosage. Therefore, the therapeutic effect of the new drug Ezetimibe combined with statins is superior to that of single drug. In order to better cure this disease, a large number of relevant literatures at home and abroad were searched. The pharmacological mechanism of ezetimibe, the new way of combining with statins, the research status and advantages of cardiovascular and cerebrovascular diseases were expounded, which provided reference for the cure of cardiovascular and cerebrovascular diseases.

Xiaoyu Zhang, Yuanshan Tang, Qinghua Wang. Progress in the application of ezetimibe combined with statins in cardiovascular and cerebrovascular diseases. Academic Journal of Medicine & Health Sciences (2023) Vol. 4, Issue 5: 77-83. https://doi.org/10.25236/AJMHS.2023.040513.

[1] Phyo Aung Zaw Zaw, Ryan Joanne, Gonzalez-Chica David A., Stocks Nigel P., Reid Christopher M., Tonkin Andrew M., Woods Robyn L., Nelson Mark R., Murray Anne M., Gasevic Danijela, Freak-Poli Rosanne. Health-related quality of life and incident cardiovascular disease events in community-dwelling older people: A prospective cohort study [J]. International Journal of Cardiology, 2021, 339.

[2] Yan Mengyao, Wang Hao, Yu Min. Epidemiological research progress of dietary pattern and cardiovascular and cerebrovascular diseases [J]. Preventive Medicine, 2020, 32 (10):1013-1017.

[3] Agarwala Anandita, Kajani Zaid, Miedema Michael D, Virani Salim S. The Role of Ezetimibe in the Treatment of Cardiovascular Disease. [J]. Current atherosclerosis reports, 2016, 18(2). 

[4] Aimei Liu, Qinghua Wu, Jingchao Guo, Irma Ares, José-Luis Rodríguez, María-Rosa Martínez- Larrañaga, Zonghui Yuan, Arturo Anadón, Xu Wang, M aría-Aránzazu Martínez. Statins: Adverse reactions, oxidative stress and metabolic interactions [J]. Pharmacology and Therapeutics, 2019, 195. 

[5] Conte Cécile, Rousseau Vanessa, Vert Charlotte, Montastruc François, Montastruc Jean-Louis, Durrieu Geneviève, Olivier Pascale. Adverse drug reactions of statins in children and adolescents: a descriptive analysis from VigiBase, the WHO global database of individual case safety reports. [J]. Fundamental & clinical pharmacology, 2020,34(4).

[6] Toth Peter P, Farnier Michel, Tomassini Joanne E, Foody JoAnne M, Tershakovec Andrew M. Statin combination therapy and cardiovascular risk reduction.[J]. Future cardiology, 2016, 12(3).

[7] Nußbaumer Barbara, Glechner Anna, Kaminski-Hartenthaler Angela, Mahlknecht Peter, Gartlehner Gerald. Ezetimibe-Statin Combination Therapy. [J]. Deutsches Arzteblatt international, 2016, 113(26). 

[8] Ouchi Yasuyoshi et al. Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized, Controlled Trial.[J]. Circulation, 2019, 140(12): 992-1003.

[9] Oh Pyung Chun, Jang Albert Youngwoo, Ha Kyungeun, et al Effect of Atorvastatin (10 mg) and Ezetimibe (10 mg) Combination Compared to Atorvastatin (40 mg) Alone on Coronary Atherosclerosis.[J]. The American journal of cardiology, 2021,154:

[10] Agarwala Anandita, Kajani Zaid, Miedema Michael D, Virani Salim S. The Role of Ezetimibe in the Treatment of Cardiovascular Disease.[J]. Current atherosclerosis reports, 2016,18(2).

[11] Cai Xiaotong, You Yingqi, Yang Xin. Research progress on individualized use of statins [J]. Practical Medicine and Clinical, 2021, 24 (10):950-955.

[12] Morieri Mario Luca, Perrone et al. Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.[J]. Cardiovascular diabetology, 2021,20(1):

[13] Sweeney Mary Ellen, Johnson Rebecca R. Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials.[J]. Expert opinion on drug metabolism & toxicology, 2007, 3(3).

[14] Luo Fei, Ruan Guiyun, Li Xiangping. Research progress on combination of statin-based lipid-lowering drugs [J].Journal of Central South Pharmacy, 2015, 13 (11):1121-1125.

[15] Li Wei, Zhu Bing, Ju Lili et al. Research progress on the relationship between blood lipid level and cardiovascular and cerebrovascular diseases [J]. China Journal of Endemic Disease Control, 2021, 36 (04):317-318.

[16] Gach O, El H Z, Lancellotti P. Acute coronary syndrome [J].Rev Med Liege, 2018, 73(5-6): 243-250.

[17] Feng Yiqing, Li Fei. Clinical study of ezetimibe combined with rosuvastatin in the treatment of premature acute myocardial infarction [J].Journal of Integrated Traditional Chinese and Western Medicine for Cardiovascular and Cerebrovascular Diseases, 2020, 18 (16):2639-2642.

[18] Mu Yu, Zhang Yunan, Shi Xiujin, et al. Guidelines, consensus and related research progress of combined lipid-lowering therapy [J].Journal of Clinical Drug Therapy, 2020, 18 (08):10-13.

[19] Han Jing, Liu Chunying, Sun Hongmei. Research progress on pathogenesis and clinical characteristics of variant angina pectoris [J].China Urban and Rural Enterprise Health, 2021, 36 (07):70-73.

[20] Gao Yongxing. Effect of intensive lipid-lowering therapy with ezetimibe on serum inflammatory factors in patients with stable angina pectoris and atrial fibrillation [D].Suzhou University, 2018.

[21] Zheng Fangfang. Effect of atorvastatin combined with ezetimibe on cardiac function and long-term prognosis in patients with coronary heart disease and heart failure [J]. Henan Medical Research, 2020, 29(35):6626-6628.

[22] Wang Kang. Clinical study of ezetimibe combined with rosuvastatin calcium tablets in the treatment of patients with coronary heart disease after PCI [J].Mongolia Medical Journal, 2021, 53 (07):860- 862. DOI:10.16096/J.cnki.nmgyxzz.2021.53.07.031.

[23] Hong Lin, Yuanming Zhang. The effect of Ezetimibe and Simvastatin Combination Therapy on percutaneous coronary intervention patients [J]. International Journal of Cardiology, 2017,242. 

[24] Chen Shiting, Sun Jinjin, Si Bingxin, Yin Xuejiao, Mou Zongyang, Luo Huilan. Effect of statins on coronary atherosclerosis in pilots [J].Air Force Medical Journal, 2017, 33 (03):149-152.

[25] Yao YK, Zhang ZQ, Qi M et al. Study on influencing factors of quality of life in patients with ischemic stroke at different stages after onset [J/OL].China General Practice:1-7[2021-09-20].

[26] Gao Suying, Yan Yinglin, Yu Kai et al. Risk factors of carotid atherosclerosis in acute ischemic stroke [J].China Journal of General Practice, 2021, 24 (03):327-332.

[27] Tan Zhongbing, Xia Le, Guan Yixiang. Effect of ezetimibe combined with lovastatin on acute cerebral infarction and carotid intima-media thickness [J]. Northwest Journal of Pharmacy, 2021, 36 (01):135-139.

[28] Li Li, Gong Hao, Li Liangyi et al. Effect of intensive lipid-lowering regimen on the degree of neurological impairment, blood lipid and Vspin levels in patients with acute cerebral infarction complicated with hypertension and dyslipidemia [J]. Hebei Medical Journal, 2019, 41 (08):1218-1220+1224.

[29] Helen Wang. Clinical observation of atorvastatin combined with ezetimibe in patients with acute ischemic stroke [D].Hainan Medical College, 2020.

[30] Kong Yana, Zhao Yongna, Li Enjing, et al. Application of a novel carotid artery stenosis prediction model in patients with transient ischemic attack [J].Chinese Journal of Geriatric Cardiovascular and Cerebrovascular Diseases, 2020, 22 (05):510-513.

[31] Li Dan, Yang Jirui. Study on the value of early stroke risk prediction scale score and serum markers in the assessment of vertigo after stroke [J].Shaanxi Medical Journal, 2021, 50 (07):864-866.

[32] Sun Youli, Xin Qingfeng. Effect of ezetimibe on blood lipid and carotid atherosclerosis in patients with transient ischemic attack [J].Journal of Community Medicine, 2016, 14 (13):54-56.

[33] Lei Yang, Gou Mengqiu, Bian Yuan et al. 2021 AHA/ASA Guidelines:Stroke Prevention in Patients with Stroke and Transient Ischemic Attack [J/OL].Medical Herald:1-8[2021-10-05].

[34] Lamb Yvette N. Rosuvastatin/Ezetimibe: A Review in Hypercholesterolemia.[J]. American journal of cardiovascular drugs: drugs, devices, and other interventions, 2020,20(4).

[35] Nußbaumer Barbara, Glechner Anna, Kaminski-Hartenthaler Angela, Mahlknecht Peter, Gartlehner Gerald. Ezetimibe-Statin Combination Therapy. [J]. Deutsches Arzteblatt international, 2016, 113(26).

[36] Aref A. Bin Abdulhak, Jennifer G. Robinson. Optimizing Statins and Ezetimibe in Guideline-Focused Management[J]. Cardiology Clinics, 2018, 36(2).

[37] Ferreira António Miguel, Marques da Silva Pedro. Defining the Place of Ezetimibe/Atorvastatin in the Management of Hyperlipidemia. [J]. American journal of cardiovascular drugs : drugs, devices, and other interventions,2017,17(3).

[38] Qin Li, Yang Yun-Bo, Yang Yi-Xin, Zhu Neng, Liu Zheng, Ni Ya-Guang, Li Shun-Xiang, Zheng Xi-Long, Liao Duan-Fang. Inhibition of macrophage-derived foam cell formation by ezetimibe via the caveolin-1/MAPK pathway. [J]. Clinical and experimental pharmacology & physiology,2016,43(2). 

[39] Xia Bin, Lin Ping, Ji Yubin, Yin Jiayu, Wang Jin, Yang Xiaoqian, Li Ting, Yang Zixun, Li Fahui, Guo Shoudong. Ezetimibe promotes CYP7A1 and modulates PPARs as a compensatory mechanism in LDL receptor-deficient hamsters. [J]. Lipids in health and disease,2020,19(1).

[40] Rong Shunxing, McDonald Jeffrey G, Engelking Luke J. Cholesterol auxotrophy and intolerance to ezetimibe in mice with SREBP-2 deficiency in the intestine.[J]. Journal of lipid research,2017, 58(10).

[41] Iryna Schlackow et al. Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease[J]. Kidney International, 2019, 96(1): 170-179.